Telmisartan Amorphous Solid Dispersion for Rapid Tablet Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Telmisartan, an angiotensin II receptor antagonist, exhibits poor solubility in aqueous systems at physiological pH, leading to challenges in achieving rapid and complete drug release from current commercial formulations.
Innovation Solution
A hot-melt extrusion process is employed to prepare telmisartan tablets by blending telmisartan with meglumine and a polymeric matrix excipient, followed by milling and compression, resulting in an amorphous solid dispersion that enhances dissolution characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If telmisartan is used in free acid form with conventional formulation methods, then manufacturing is simple, but dissolution performance is poor due to very poor solubility in aqueous systems at physiological pH
Solution Approach 1:
The patent changes the physical-chemical parameters of telmisartan by converting it from crystalline form to amorphous form through hot-melt extrusion processing. This parameter change dramatically improves solubility and dissolution performance, allowing the drug to release rapidly in physiological pH conditions without requiring complex formulation modifications
Solution Approach 2:
The patent creates a composite material system by combining telmisartan with specific excipients (basic agents like meglumine or magnesium carbonate, and polymeric materials) through hot-melt extrusion. This composite approach enhances dissolution performance while maintaining manufacturing feasibility through a single-step processing method
2Productivity
If immediate release is achieved through conventional methods, then drug release is rapid, but solubility limitations prevent complete dissolution of telmisartan
Solution Approach 1:
The patent utilizes phase transition by transforming telmisartan from crystalline phase to amorphous phase during hot-melt extrusion. This phase change eliminates the solubility limitations of the crystalline form, enabling both rapid release and complete dissolution of the drug substance in physiological conditions
Solution Approach 2:
The patent introduces basic agents and polymeric materials as intermediaries that interact with telmisartan during hot-melt extrusion. These intermediaries facilitate complete dissolution by preventing drug precipitation and maintaining solubility throughout the release process, ensuring both speed and completeness of drug release
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process improves in-vitro dissolution performance of telmisartan across the physiologically relevant pH range, surpassing commercial formulations, with rapid drug release within 30-60 minutes.
Implementation Method 1
processing telmisartan, meglumine as the basic agent and optionally a polymeric matrix excipient by hot melt extrusion at a barrel temperature of 120-180°C to obtain an extrudate of telmisartan
Implementation Method 2
Hot-melt extrusion means processing a powdered premix of an active agent such as telmisartan and functional excipients (e.g. polymers and/or pH modifiers) in an extruder at elevated temperature and mechanical stress
Implementation Method 3
The polymeric matrix excipient of the present disclosure is chosen to form an amorphous solid dispersion with the active agent telmisartan, i.e. telmisartan is embedded into the polymer matrix
Data Source
AI summary
A process for the preparation of an immediate release tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.